Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers

NCT03215511 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03215511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03215511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
July 3, 2017
Completion date
January 30, 2023
Enrollment
81 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors harboring ntrk fusion